COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B8ZP
|
|||
| Drug Name |
PD-144418
|
|||
| Synonyms |
PD144418; PD 144418; ZINC5862; GTPL10731; BDBM50251208; AKOS024457192; NCGC00378668-01; HY-108512; CS-0029071; Q27456166
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Investigative | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N2O
|
|||
| Canonical SMILES |
CCCN1CCC=C(C1)C2=CC(=NO2)C3=CC=C(C=C3)C
|
|||
| InChI |
1S/C18H22N2O/c1-3-10-20-11-4-5-16(13-20)18-12-17(19-21-18)15-8-6-14(2)7-9-15/h5-9,12H,3-4,10-11,13H2,1-2H3
|
|||
| InChIKey |
FOQRKFCLRMMKAT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 154130-99-1
|
|||
| PubChem Compound ID | ||||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN opioid receptor sigma 1 (OPRS1) | Target Info | Antagonist | [2] |
| PD-144418 binds to Sigma receptors, which participates in ER stress response and thus leads to inhibition of its interaction with SARS-CoV-2 Nsp6 protein. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology. 1997 Jan;36(1):51-62. | |||
| 2 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.